Full Press Release Details
Melbourne (Australia) | 01 May 2024
Telix today announces five oral abstract presentations featuring the Company’s late-stage theranostic programs in urology at the American Urological Association (AUA) Annual Meeting being held in San Antonio from May 3 – 6, 2024.
Presentations cover: ProstACT GLOBAL Phase III study of TLX591 ( 177 Lu rosopatamab tetraxetan), Telix’s first-in-class investigational prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate (rADC) therapy for prostate cancer; and Illuccix® ( 68 Ga-PSMA-11), Telix’s approved positron emission tomography (PET) imaging agent for prostate cancer.
In addition, the Company will be presenting two thought leadership sessions at the AUA Product Theater (booth #1159), featuring key opinion leaders in urologic oncology and theranostics – one on the future of kidney cancer detection and management (including the potential role of TLX250-CDx Zircaix® 1 PET in clear cell renal cell carcinoma), and one on Illuccix® and PSMA imaging for the initial staging of prostate cancer.
Come and meet with us in person at booth #631 to discuss Telix’s theranostic programs targeting PSMA, our carbonic anhydrase IX (CAIX) targeting programs in kidney, bladder and other CAIX-expressing cancers, our associated medical devices and artificial intelligence (AI), and opportunities for collaboration.
AUA oral presentation details are as follows (all times CDT):
Title: Analyzing the percentage of positive 68 Ga-PSMA-PET/CT scans based on PSA ranges across distinct indications for the scan
Presenter: Maya Nicole Ataya, MD, Research Fellow at Indiana University
Date and Time: Friday, May 3 | 7:30 am – 7:40 am
Session: PD01: Prostate Cancer: Advanced (including Drug Therapy) I
Location: 301A
Title: Predicting positive 68 Ga-PSMA PET/CT scans in biochemical recurrence following prostatectomy
Presenter: Maya Nicole Ataya, MD, Research Fellow at Indiana University
Date and Time: Friday, May 3 | 5:00 pm – 5:10 pm
Session: PD17: Prostate Cancer: Staging I
Location: 225D
Title: Characterizing prostate cancer risk with 68 Ga-PSMA-11 PET imaging and artificial intelligence (AI)
Presenter: Simon Wail, Director of AI Research, Telix Pharmaceuticals
Date and Time: Sunday, May 5 | 7:50 am – 8:00 am
Session: PD36: Surgical Technology & Simulation: Artificial Intelligence III
Location: 301A
Title: ProstACT GLOBAL: A Phase III study of 177-lutetium rosopatamab tetraxetan plus standard of care vs. standard of care alone for adult patients with PSMA positive metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibition
Presenter: Scott Tagawa, Professor of Medicine & Urology Weill Cornell Medicine
Date and Time: Sunday, May 5 | 2:20 pm – 2:28 pm
Session: Clinical Trials in Progress, Cancer
Location: Learning Lab
Title: Identifying sites of prostate cancer recurrence in 68 Ga-PSMA PET/CT based on scan indication
Presenter: Maya Nicole Ataya, MD, Research Fellow at Indiana University
Date and Time: Sunday, May 5 | 2:20 pm – 2: 30 pm
Session: PD45: Prostate Cancer: Staging II
Location: 301A
Telix AUA Product Theater listings (booth #1159):
Title: The future of kidney cancer detection and management
Presenters:
Learning Objectives:
Date and Time: Saturday, May 4 | 2:30 pm – 3:15 pm
Location: Science and Technology Hall, Booth #1159
To secure a seat, please visit our website here .
Title: Illuccix® and PSMA imaging for the initial staging of prostate cancer
Presenters:
Learning Objectives:
Date and Time: Sunday, May 5 | 2:30 pm – 3:15 pm
Location: Science and Technology Hall, Booth #1159
To secure a seat, please visit our website here .
Space for both theater sessions is limited so early registration is recommended.
Illuccix® has been approved by the U.S. Food and Drug Administration (FDA), by the Australian Therapeutic Goods Administration (TGA), and by Health Canada. No other Telix product has received a marketing authorisation in any jurisdiction
• Brand name subject to final regulatory approval. ↩︎